論文 - 詳細
| RRC ID | 43801 |
|---|---|
| 著者 | Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T. |
| タイトル | SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. |
| ジャーナル | Int J Cancer |
| Abstract |
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis for which an effective therapy remains to be established. This study investigated the therapeutic potential of gene delivery using suppressor of cytokine signaling 1 (SOCS-1), an endogenous inhibitor of intracellular signaling pathways, for the treatment of MPM. We infected MPM cells (MESO-4, H28 and H226) with adenovirus-expressing SOCS-1 vector to examine the effect of SOCS-1 overexpression on MPM cells. We evaluated the antitumor effect of SOCS-1 gene delivery combined with cisplatin plus pemetrexed by cell proliferation, apoptosis and invasion assay. We also investigated the regulation of NF-κB and STAT3 signaling related to apoptotic pathways. Furthermore, we evaluated the inhibition of tumor growth by SOCS-1 gene delivery combined with cisplatin plus pemetrexed in vivo. SOCS-1 gene delivery cooperated with cisplatin plus pemetrexed to inhibit cell proliferation, invasiveness and induction of apoptosis in MPM cells. SOCS-1 regulated NF-κB and STAT3 signaling to induce apoptosis in MESO-4 and H226 cells. Furthermore, SOCS-1 gene delivery cooperated with cisplatin plus pemetrexed to regulate NF-κB signaling and significantly inhibit tumor growth of MPM in vivo. These results suggest that SOCS-1 gene delivery has a potent antitumor effect against MPM and a potential for clinical use in combination with cisplatin plus pemetrexed. |
| 巻・号 | 132(2) |
| ページ | 459-71 |
| 公開日 | 2013-1-15 |
| DOI | 10.1002/ijc.27611 |
| PMID | 22532243 |
| MeSH | Adenoviridae / genetics Animals Antineoplastic Combined Chemotherapy Protocols / pharmacology Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Apoptosis Cell Line, Tumor Cell Movement Cell Proliferation / drug effects Cell Survival / drug effects Cisplatin / administration & dosage Combined Modality Therapy Enzyme Activation Female Gene Expression Genetic Therapy Genetic Vectors Glutamates / administration & dosage Guanine / administration & dosage Guanine / analogs & derivatives Humans Inhibitor of Apoptosis Proteins / metabolism Interferon-gamma / pharmacology Interferon-gamma / physiology Mesothelioma / pathology Mesothelioma / therapy* Mice Mice, Inbred ICR Mice, Nude NF-kappa B / metabolism Neoplasm Invasiveness Pemetrexed Pleural Neoplasms / pathology Pleural Neoplasms / therapy* STAT3 Transcription Factor / metabolism Signal Transduction Suppressor of Cytokine Signaling 1 Protein Suppressor of Cytokine Signaling Proteins / genetics* Suppressor of Cytokine Signaling Proteins / metabolism Tumor Burden / drug effects Xenograft Model Antitumor Assays |
| IF | 5.145 |
| 引用数 | 20 |
| WOS 分野 | ONCOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | ACC-MESO-4(RCB2293) |